APA (7th ed.) Citation

BA, W., GK, S., MS, G., AB, E., AJ, B., B, H., . . . AM, T. (2025). Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(11), 1358. https://doi.org/10.1200/JCO-24-02524

Chicago Style (17th ed.) Citation

BA, Wilky, et al. "Botensilimab (Fc-enhanced Anti-cytotoxic Lymphocyte-association Protein-4 Antibody) Plus Balstilimab (anti-PD-1 Antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 11 (2025): 1358. https://doi.org/10.1200/JCO-24-02524.

MLA (9th ed.) Citation

BA, Wilky, et al. "Botensilimab (Fc-enhanced Anti-cytotoxic Lymphocyte-association Protein-4 Antibody) Plus Balstilimab (anti-PD-1 Antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 11, 2025, p. 1358, https://doi.org/10.1200/JCO-24-02524.